Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
30 Novembre 2023 - 7:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in gene
therapies in the inner ear, announces that the Company’s
shareholders are invited to participate in the Combined General
Meeting, to be held on Wednesday, December 20, 2023, at 2 pm CET in
the premises of the hotel Square Louvois, located at 12, rue de
Louvois, 75002, Paris, France.
The prior notice of meeting comprising the agenda and draft
resolutions was published in the BALO (Bulletin des Annonces
Légales Obligatoires) on November 15, 2023, and the convening
notice shall be published in a newspaper empowered to publish legal
notices on December 1, 2023.
The documents provided for in articles R.22-10-23 of the French
Commercial Code, are available for consultation on the company’s
website mentioned below as of today, the twenty-first day prior to
the General Meeting: www.sensorion.com.
In accordance with articles R.225-83 of the French Commercial
Code, documents are available for the shareholders from the time
the meeting is convened. In accordance with applicable
regulations:
- any registered shareholders can, until the fifth day
(inclusive) before the Meeting, request from the Company to receive
these documents, including at their request, by way of an
electronic mail. For holders of bearer shares, the exercise of this
right is subject to the presentation of a certificate of attendance
in the bearer share accounts kept by the empowered
intermediary;
- any shareholder may consult these documents at the registered
office of the Company.
For any questions relating to the Annual General Meeting of
December 20, 2023, shareholders are invited to send an email to
contact@sensorion-pharma.com.
The conditions for holding and taking part in this Combined
Shareholders’ General Meeting may evolve depending on the health,
regulatory and legal requirements in place. In general,
shareholders are invited to regularly consult the section dedicated
to the General Meeting on the Company's website
www.sensorion.com.
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which
specializes in the development of novel therapies to restore, treat
and prevent hearing loss disorders, a significant global unmet
medical need.
Sensorion has built a unique R&D technology platform to
expand its understanding of the pathophysiology and etiology of
inner ear related diseases, enabling it to select the best targets
and mechanisms of action for drug candidates. It has two gene
therapy programs aimed at correcting hereditary monogenic forms of
deafness, developed in the framework of its broad strategic
collaboration focused on the genetics of hearing with the Institut
Pasteur. SENS-501 (OTOF-GT) targets deafness caused by mutations of
the gene encoding for otoferlin and GJB2-GT targets hearing loss
related to mutations in GJB2 gene to potentially address important
hearing loss segments in adults and children. The Company is also
working on the identification of biomarkers to improve diagnosis of
these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small
molecule programs for the treatment and prevention of hearing loss
disorders. Sensorion’s clinical-stage portfolio includes one Phase
2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2
proof of concept clinical study of SENS-401 in Cisplatin-Induced
Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of
SENS-401 in patients scheduled for cochlear implantation. A Phase 2
study of SENS-401 was also completed in Sudden Sensorineural
Hearing Loss (SSNHL) in January 2022.
www.sensorion.com
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
2022 full year financial report published on March 30, 2023, and
available on our website and to the development of economic
conditions, financial markets and the markets in which Sensorion
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Sensorion or not
currently considered material by Sensorion. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Sensorion to be
materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231129001061/en/
Investor Relations Noemie Djokovic, Investor Relations
and Communications Associate ir.contact@sensorion-pharma.com
International Media Relations Ulysse Communication
Pierre-Louis Germain / 00 33 (0)6 64 79 97 51
plgermain@ulysse-communication.com Bruno Arabian / 00 00(0)6 87 88
47 26 barabian@ulysse-communication.com
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024